검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | TNF Inhibitor |
Overview Company | Hoffmann-La Roche |
Overview Modality | ANTIBODY |
Overview Target | Ulcerative Colitis |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
MoA Mechanism | target one inflammatory pathway |
MoA Biomarker | biomarkers, improved remission rates (MDA, DAPSA), and prolonged drug survival by restoring adipokine balance |
PK/PD Half-life | 0.75 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | High 12-month persistence and effectiveness of IL-23 inhibitors in psoriatic arthritis: a multicenter retrospective real-world study from Argentina.. Interleukin-23 inhibitors (IL-23i) are effective in psoriatic arthritis (PsA) in randomized trials; however, real-world data from Latin America remain limited. We described baseline characteristics and treatment line at IL-23i initiation, physician-r… |
Clinical Primary efficacy | ORR 6.35% |
Clinical ORR | 6.35% |
Clinical Result source | ClinicalTrials.gov NCT00124982 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | TNF Inhibitor |
Overview Company | Hoffmann-La Roche |
Overview Modality | ANTIBODY |
Overview Target | Ulcerative Colitis |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
MoA Mechanism | target one inflammatory pathway |
MoA Biomarker | biomarkers, improved remission rates (MDA, DAPSA), and prolonged drug survival by restoring adipokine balance |
PK/PD Half-life | 0.75 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | High 12-month persistence and effectiveness of IL-23 inhibitors in psoriatic arthritis: a multicenter retrospective real-world study from Argentina.. Interleukin-23 inhibitors (IL-23i) are effective in psoriatic arthritis (PsA) in randomized trials; however, real-world data from Latin America remain limited. We described baseline characteristics and treatment line at IL-23i initiation, physician-r… |
Clinical Primary efficacy | ORR 6.35% |
Clinical ORR | 6.35% |
Clinical Result source | ClinicalTrials.gov NCT00124982 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교